Latest Capital Raise News

Trigg Minerals Limited has voluntarily suspended trading on the ASX as it prepares to announce a significant capital raise, signaling potential shifts in its financial strategy.

Investigator Resources appoints Lachlan Wallace as Managing Director and secures $4.3 million to accelerate exploration at the Paris Silver Project and beyond.

Red Mountain Mining has successfully raised $0.65 million through a heavily oversubscribed placement, enabling accelerated exploration at its Armidale Antimony-Gold Project and other gold assets in Australia and Canada.

Wide Open Agriculture Limited reminds shareholders of the imminent closing of its Securities Purchase Plan, offering shares at a discounted price with free options, while gearing up for an investor webinar to discuss company progress.

archTIS Limited has secured A$7.5 million through a discounted share placement to fund expansion in the U.S. defence sector, deepen strategic partnerships, and accelerate product innovation focused on secure data collaboration.

Prescient Therapeutics has launched a $7 million Share Purchase Plan at a notable discount to fund the next phase of clinical trials for its promising PTX-100 cancer therapy. The capital raise aims to accelerate progress toward regulatory approval and patient access.

Challenger Gold Limited advances its Hualilan Gold Project towards early production via a toll milling agreement starting in late 2025, underpinned by a robust 2.8 million ounce gold equivalent resource and strong project economics.

Harvest Technology Group has raised $500,000 through unsecured convertible notes with a 15% annual interest rate, supporting its strategic three-year profit plan. The notes include attached options exercisable over two years, pending shareholder approval.

Copper Search Limited has secured two key exploration licences in South Australia's Eromanga Basin for Heavy Mineral Sands, setting the stage for a fully funded drilling campaign later this year. The company is also progressing copper-gold projects in New South Wales with government co-funding applications underway.

Paradigm Biopharmaceuticals has locked in a $27 million USD convertible note facility to fully fund its pivotal Phase 3 trial for knee osteoarthritis, ensuring operational momentum through key clinical milestones.

Laramide Resources has announced a $10 million private placement to fund critical US permitting and corporate activities, with major shareholder Boss Energy backing the raise.

Metro Performance Glass has locked in a minimum $15 million capital raise and a new three-year loan facility, positioning itself for growth with Amari Metals Australia set to become the majority shareholder.